In vitro Antioxidant Activity of Valeriana officinalis Against Different Neurotoxic Agents
- 633 Downloads
Valeriana officinalis L. (Valerian) is widely used as a traditional medicine to improve the quality of sleep. Although V. officinalis have been well documented as promising pharmacological agent; the exact mechanisms by which this plant act is still unknown. Limited literature data have indicated that V. officinalis extracts can exhibit antioxidant properties against iron in hippocampal neurons in vitro. However, there is no data available about the possible antioxidant effect of V. officinalis against other pro-oxidants in brain. In the present study, the protective effect of V. officinalis on lipid peroxidation (LPO) induced by different pro-oxidant agents with neuropathological importance was examined. Ethanolic extract of valerian (0–60 μg/ml) was tested against quinolinic acid (QA); 3-nitropropionic acid; sodium nitroprusside; iron sulfate (FeSO4) and Fe2+/EDTA induced LPO in rat brain homogenates. The effect of V. officinalis in deoxyribose degradation and reactive oxygen species (ROS) production was also investigated. In brain homogenates, V. officinalis inhibited thiobarbituric acid reactive substances induced by all pro-oxidants tested in a concentration dependent manner. Similarly, V. officinalis caused a significant decrease on the LPO in cerebral cortex and in deoxyribose degradation. QA-induced ROS production in cortical slices was also significantly reduced by V. officinalis. Our results suggest that V. officinalis extract was effective in modulating LPO induced by different pro-oxidant agents. These data may imply that V. officinalis extract, functioning as antioxidant agent, can be beneficial for reducing insomnia complications linked to oxidative stress.
KeywordsValeriana officinalis Ethanolic extract Pro-oxidant agents TBARS Deoxyribose degradation Oxidative stress
The financial support by CAPES/SAUX/PROAP, VITAE Fundation, CNPq, FAPERGS, ICTP and FINEP research grant ‘‘Rede Instituto Brasileiro de Neurociência (IBN-Net)’’ # 01.06.0842-00 is gratefully acknowledged.
- 1.World Health Organization (1992) The ICD-10 classification of mental and behavioral disorders. World Health Organization, GenevaGoogle Scholar
- 2.Ancoli-Israel S, Roth T (1999) Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I Sleep 22:S347–S353Google Scholar
- 8.Halliwell B, Gutteridge JMC (eds) (1999) Free radicals in biology and medicine, 3rd edn. Oxford University Press, Oxford, p 936Google Scholar
- 13.Richman A, Witkowski JP (1998) 4th Annual herbal products sales survey. Whole Foods 21:19–26Google Scholar
- 15.Meoli AL, Rosen C, Kristo D, Kohrman M, Gooneratne N, Aguillard RN, Fayle R, Troell R, Touwnsend D, Claman D, Hoban T, Mahowald M (2005) Clinical practice review committee of the American academy of sleep medicine. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med 2:173–187Google Scholar
- 20.Oliveira DM, Barreto G, De Andrade DEV, Saraceno E, Aon-Bertolino L, Capani F, El Bacha RS, Giraldez LD (2009) Cytoprotective effect of Valeriana officinalis extract on an in vitro experimental model of Parkinson disease. Neurochem Res 34:215–220. doi: 10.1007/s11064-008-9749-y CrossRefGoogle Scholar
- 25.Monserrat JM, Geracitano LA, Pinho GLL, Vinagre TM, Faleiros M, Alciati JC, Bianchini A (2003) Determination of lipid peroxides in invertebrates tissues using the Fe(III). Xylenol orange complex formation. Arch Environ Contam Toxicol 45:177–183. doi: 10.1007/s00244-003-0073-x PubMedCrossRefGoogle Scholar
- 26.Pérez-Severiano P, Rodríguez-Pérez M, Pedraza-Chaverrí J, Maldonado PD, Medina Campos ON, Ortíz-Plata A, Sánchez-García A, Villeda-Hernández J, Galván-Arzate S, Aguilera P, Santamaría A (2004) S-allylcysteine, a garlic-derived antioxidant, ameliorates quinolinic acid-induced neurotoxicity and oxidative damage in rats. Neurochem Int 45:1175–1183. doi: 10.1016/j.neuint.2004.06.008 PubMedCrossRefGoogle Scholar
- 29.Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Ávila DS, Burger ME, Calixto JB, Rocha JBT, Ferreira J (2007) Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry 31:1478–1486. doi: 10.1016/j.pnpbp.2007.06.028 PubMedCrossRefGoogle Scholar
- 32.Pereira RP, Fachinetto R, Prestes AS, Puntel RL, Silva GNS, Heinzmann BM, Boschetti TK, Athayde ML, Bürger ME, Morel AF, Morsh VM, Rocha JBT (2009) Antioxidant effects of different extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citrates. Neurochem Res (in press). doi: 10.1007/s11064-008-9861-z
- 36.Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105–7109. doi: 10.1073/pnas.92.15.7105 PubMedCrossRefGoogle Scholar